A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

NCT01380769 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: CRLX101
OTHER: Best Supportive Care

Sponsor

NewLink Genetics Corporation